Business Context and Reporting Period
Neurosense Therapeutics Ltd. filed a Form 6-K on August 16, 2022, reporting on its Phase IIb PARADIGM clinical trial for PrimeC, a drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress.
Material Changes and Clinical Progress
- Patient Enrollment: The company reported strong enrollment, with 20 out of 69 planned patients enrolled, representing approximately 30% of the target.
- Safety Profile: PrimeC has demonstrated safety and tolerability in the current Phase IIb study.
- Geographic Expansion: The Israel site is actively recruiting, with plans to add clinical centers in the United States and Europe in early Q4 2022.
Outlook and Management Commentary
Management expects top-line results from the PARADIGM study in the first half of 2023. The company is proceeding with a competitive recruitment strategy to meet enrollment targets ahead of the expansion into US and European sites.
Key Facts for Investor Verification
- Verify the total number of patients enrolled (20) against the total planned (69) to confirm the 30% enrollment rate.
- Confirm the timeline for adding US and European clinical centers in Q4 2022.
- Monitor the expected release of top-line results in H1 2023.
- Review subsequent filings for financial data, as this 6-K contains no financial statements.